Trial · NCT06572813
Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer
NCT06572813, Phase 1, Phase 2, Recruiting, First Affiliated Hospital of Zhejiang University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer. Trials, record NCT06572813. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06572813
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer
- NCT number
- NCT06572813
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 63 participants, estimated
- Lead sponsor
- First Affiliated Hospital of Zhejiang University
- Conditions
- Pancreas Cancer
- Interventions
- Bortezomib Injection, Sintilimab, mFOLFIRINOX
- First posted
- 2024-08-27
- Last updated
- 2025-01-10
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Phase 1: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 | Up to 2 years. | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0，including Complete Blood Count, liver function, renal function lab test and other blood test will be evaluated by using CTCAE 5.0 during study. |
| Primary | Phase 2: Objective reponse rate (ORR) | Up to 2 years | The proportion of patients who had tumor evaluated as PR according to RECIST1.1 criteria during phase 2 |
| Secondary | Disease control rate (DCR) | Up to 2 years | The proportion of patients who had tumor evaluated as PR or SD according to RECIST1.1 criteria during phase 2 |
| Secondary | Duration of remission （DoR） | Up to 2 years | The time from the first assessment of the tumor as CR or PR to the first assessment of PD or death from any cause during phase 2 |
| Secondary | Progression-free survival （PFS） | Up to 2 years | The time from enrolled to disease pregression or death from any cause during phase 2 |
| Secondary | Overall survival (OS) | Up to 2 years | The time from enrolled to death from any cause during phase 2 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06572813
GET https://conductscience.org/api/trials/v1/NCT06572813/registered